SUPERA PERIPHERAL STENT SYSTEM
Abbott Vascular (Idef Technologies Inc) · Decision date Mar 28, 2014
What did the FDA approve?
FDA records P120020 as an original PMA application. The recorded decision is approval, dated Mar 28, 2014.
FDA approval order statement
APPROVAL FOR THE SUPERA PERIPHERAL STENT SYSTEM. THIS DEVICE IS INDICATED TO IMPROVE LUMINAL DIAMETER IN THE TREATMENT OF PATIENTS WITH SYMPTOMATIC DE NOVO OR RESTENOTIC NATIVE LESIONS OR OCCLUSIONS OF THE SUPERFICIAL FEMORAL ARTERY (SFA) AND/OR PROXIMAL POPLITEAL ARTERY, WITH REFERENCE VESSEL DIAMETERS OF 4.0 TO 6.5 MM, AND LESION LENGTHS UP TO 140 MM.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 28, 2014
Regulatory record facts
- Identifier
- P120020
- Regulatory pathway
- Premarket approval application
- Product code
- NIP
- Decision code
- APPR
- Decision date
- Mar 28, 2014
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Product code
- NIP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P120020 received
Application receipt date recorded by FDA.
P120020 · FDA decision
APPR
P120020/S037 · Related supplement
Supera Peripheral Stent System
Timeline entries are records held by MedtechLedger for P120020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Vascular (Idef Technologies Inc)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


